AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025, the company's independently developed mRNA shingles vaccine has recently received clinical ...

Johns Hopkins scientists develop mRNA "booster" as potential new way to treat rare genetic diseases marked by too low levels ...

RNA vaccines were first developed years ago to target cancers and now they're really starting to show promise.

With the help of mRNA technology proven effective during the COVID era, researchers are now closer than ever to creating ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

"By integrating our expertise in mRNA design and nanoparticle delivery with IPA’s cutting-edge antibody discovery and engineering capabilities, we can address longstanding challenges in antigen ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...